Adam C Palmer (Adam Palmer)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 34

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

bioRxiv : the preprint server for biology

Blood cancer discovery

University of North Carolina at Chapel Hill

Harvard University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of North Carolina at Chapel Hill

United States

Assistant Professor :: Pharmacology

Education History

Harvard University

United States

PHD :: Systems Biology

Publications

Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (4) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
SYNERGISTIC DRUG COMBINATIONS PROMOTE THE DEVELOPMENT OF RESISTANCE IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery (2024)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (4) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (4) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
SYNERGISTIC DRUG COMBINATIONS PROMOTE THE DEVELOPMENT OF RESISTANCE IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (4) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood cancer discovery 5 (2) (2024)
Emily Mason-Osann, Amy E Pomeroy, Adam C Palmer, Jerome T Mettetal
Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia. Blood cancer discovery 5 (2) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (4) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism. Molecular cancer therapeutics 23 (7) (2024)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. Molecular cancer therapeutics (2024)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-specific activity of precision medicines in the NCI-MATCH trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-specific activity of precision medicines in the NCI-MATCH trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jung-Kuei Chen, Karl A Merrick, Yi Wen Kong, Anita Izrael-Tomasevic, George Eng, Erika D Handly, Jesse C Patterson, Ian G Cannell, Lucia Suarez-Lopez, Aaron M Hosios, Anh Dinh, Donald S Kirkpatrick, Kebing Yu, Christopher M Rose, Jonathan M Hernandez, Haeun Hwangbo, Adam C Palmer, Matthew G Vander Heiden, Ömer H Yilmaz, Micheal B Yaffe
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types. bioRxiv : the preprint server for biology (2023)
Ivvone Zhou, Deborah Plana, Adam C Palmer
Tumor-specific activity of precision medicines in the NCI-MATCH trial. medRxiv : the preprint server for health sciences (2023)
Haeun Hwangbo, Sarah C Patterson, Andy Dai, Deborah Plana, Adam C Palmer
Additivity predicts the efficacy of most approved combination therapies for advanced cancer. Nature cancer (2023)
Jung-Kuei Chen, Karl A Merrick, Yi Wen Kong, Anita Izrael-Tomasevic, George Eng, Erika D Handly, Jesse C Patterson, Ian G Cannell, Lucia Suarez-Lopez, Aaron M Hosios, Anh Dinh, Donald S Kirkpatrick, Kebing Yu, Christopher M Rose, Jonathan M Hernandez, Haeun Hwangbo, Adam C Palmer, Matthew G Vander Heiden, Ömer H Yilmaz, Micheal B Yaffe
An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types. bioRxiv : the preprint server for biology (2023)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)
Sarah C Patterson, Amy E Pomeroy, Adam C Palmer
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism. bioRxiv : the preprint server for biology (2023)
Adam C Palmer, Benjamin Izar, Haeun Hwangbo, Peter Karl Sorger
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (2) (2022)
Deborah Plana, Geoffrey G Fell, Brian M Alexander, Adam C Palmer, Peter Karl Sorger
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects. Nature communications 13 (1) (2022)
Deborah Plana, Adam C Palmer, Peter Karl Sorger
Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer discovery 12 (3) (2022)
Fabrizio Clarelli, Adam C Palmer, Bhupender Singh, Merete Storflor, Silje Lauksund, Ted Cohen, Sören Abel, Pia Abel Zur Wiesch
Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLoS computational biology 16 (8) (2020)
Adam C Palmer, Deborah Plana, Hui Gao, Joshua M Korn, Guizhi Yang, John Green, Xiamei Zhang, Roberto Velazquez, Margaret E McLaughlin, David A Ruddy, Colleen Kowal, Julie Muszynski, Caroline Bullock, Stacy Rivera, Daniel P Rakiec, GiNell Elliott, Paul Fordjour, Ronald Meyer, Alice Loo, Esther Kurth, Jeffrey A Engelman, Hans Bitter, William R Sellers, Juliet A Williams, Peter Karl Sorger
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts. Cancer research 80 (19) (2020)
Adam C Palmer, Christopher Chidley, Peter Karl Sorger
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. eLife 8 (2019)
Nan Hao, Michael T Crooks, Adam C Palmer, Ian B Dodd, Keith E Shearwin
RNA polymerase pausing at a protein roadblock can enhance transcriptional interference by promoter occlusion. FEBS letters 593 (9) (2019)
Raphael Koch, Amanda L Christie, Jennifer L Crombie, Adam C Palmer, Deborah Plana, Kay Shigemori, Sara N Morrow, Alexandria Van Scoyk, Wenchao Wu, Elizabeth A Brem, J Paul Secrist, Lisa Drew, Alwin G Schuller, Justin Cidado, Anthony Letai, David M Weinstock
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood 133 (6) (2018)
Zohar B Weinstein, Nurdan Kuru, Szilvia Kiriakov, Adam C Palmer, Ahmad S Khalil, Paul A Clemons, Muhammad H Zaman, Frederick P Roth, Murat Cokol
Modeling the impact of drug interactions on therapeutic selectivity. Nature communications 9 (1) (2018)
Nan Hao, Adam C Palmer, Alexandra Ahlgren-Berg, Keith E Shearwin, Ian B Dodd
The role of repressor kinetics in relief of transcriptional interference between convergent promoters. Nucleic acids research 44 (14) (2016)
Adam C Palmer
Chemical probes: The many genes of drug mechanism. Nature chemical biology 12 (2) (2016)

Adam C Palmer.css-eqlu8i{font-size:small;padding-left:4px;} (Adam Palmer)

Publication Activity (10 Years)

Top Topics

Top Venues

Adam C Palmer (Adam Palmer)